Loading...
Vascular epidermal growth factor (VEGF)-targeted tyrosine kinase inhibitors have become a standard of care for patients with advanced, clear-cell renal cancer. Axitinib, a potent selective inhibitor of VEGF receptors, was shown to improve progression-free survival (PFS) and objective response versus sorafenib in such patients when administered as second-line therapy (NEJM JW Oncol Hematol Nov 15 2011).
To determine whether dose titration of first-line axitinib would improve outcomes in advanced renal carcinoma, investigators conducted an industry-funded, phase II, international, randomized, double-blind study involving 213 previously untreated patients with histologically confirmed metastatic renal cell disease with a clear cell component. P…